{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:27:11Z","timestamp":1761895631099},"reference-count":59,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":8347,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1990,5]]},"abstract":"<jats:p>Compared with aminoglycosides, chloramphenicol, sulfonamides, tetracyclines, and even penicillins, the cephalosporins represent a remarkably safe class of antibiotics. Among the cephalosporins, the extended spectrum, third generation agents developed generally produce few side effects and appear to be less allergenic than the penicillins. Nephrotoxicity has not been a problem at recommended doses. Some third generation agents can cause hypoprothrombinemia if not administered with vitamin K, and disulfiram\u2010like reactions occur with some agents because of the presence of a thiomethyl tetruzole moiety affixed to the cephem nucleus. There is a greater incidence of diarrhea associated with the agents excreted through a primarily biliary route, and this may contribute to the selection of drug resistant bacteria. Some agents are less active against staphylococci and their use may result in an increased incidence of superinfection or overgrowth of enterococci. If attention is given to the potential for adverse effects, many of these problems can be avoided and the third generation cephalosporins can be used safely in hospitals, nursing homes, and home care settings.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1990.tb03476.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T21:35:53Z","timestamp":1362778553000},"page":"396-403","source":"Crossref","is-referenced-by-count":32,"title":["Third Generation Cephalosporins: Safety Profiles After 10 Years of Clinical Use"],"prefix":"10.1002","volume":"30","author":[{"given":"Harold C.","family":"Neu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.3.403"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90268-2"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_2.S368"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-2-204"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198700342-00011"},{"key":"e_1_2_1_7_2","first-page":"358","article-title":"Toxic and adverse reactions encountered with new beta\u2010lactam antibiotics","volume":"1984","author":"Parry MF","journal-title":"Bull NY Acad Med"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198710000-00037"},{"key":"e_1_2_1_9_2","first-page":"54","article-title":"Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia","volume":"77","author":"Baumgartner JD","year":"1984","journal-title":"Am J Med"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198501000-00007"},{"key":"e_1_2_1_11_2","first-page":"1048","article-title":"Ceftriaxone therapy in pediatric patients","volume":"137","author":"Harrison CJ","year":"1983","journal-title":"Am J Dis Child"},{"key":"e_1_2_1_12_2","first-page":"1241","article-title":"Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children","volume":"1","author":"Rio M","year":"1983","journal-title":"Lancet"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.1.65"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80801-4"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198507000-00006"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1001\/jama.1985.03350480067021","article-title":"Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis","volume":"253","author":"Lin T\u2010Y","year":"1985","journal-title":"JAMA"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.5.637"},{"key":"e_1_2_1_18_2","first-page":"133","article-title":"Considerations regarding clinical safety and tolerability of antibiotics in serious and nosocomial infections","volume":"4","author":"Smith CR","year":"1981","journal-title":"Clin Ther"},{"key":"e_1_2_1_19_2","unstructured":"SchaadUB Gianella\u2010BorradoriA SuterS:Ceftriaxone (CRO) versus cefuroxime (CSM) for bacterial meningitis in infants and children.Abstract #789 27th Interscience Conference on Antimicrobial Agents and Chemotherapy October 47 1987; New York New York."},{"key":"e_1_2_1_20_2","unstructured":"SchaadUB WedgwoodH TschaeppelerH:Gallbladder precipitations associated with ceftriaxone (CRO) therapy in infants and children.Abstract #555 28th Interscience Conference on Antimicrobial Agents and Chemotherapy October 2326 1988; Los Angeles California."},{"key":"e_1_2_1_21_2","unstructured":"Heim\u2010DuthoyK CapertonE MatzkeG PetersonP:Biliary pseudolithiasis during ceftriaxone (C)therapy. Abstract #556 28th Interscience Conference on Antimicrobial Agents and Chemotherapy October 2326 1988; Los Angeles California."},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/10.6.483"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198100221-00017"},{"issue":"1","key":"e_1_2_1_24_2","first-page":"544","article-title":"Cefoperazone in the treatment of lower respiratory tract infections","volume":"9","author":"Moser J","year":"1981","journal-title":"Infection"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_1.S161"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_1.S165"},{"issue":"1","key":"e_1_2_1_27_2","first-page":"73","article-title":"A randomized, controlled trial of cefoperazone vs cefamandole\u2014tobramycin in the treatment of putative, severe infections with gram\u2010negative bacilli","author":"Warren JW","year":"1983","journal-title":"Rev Infect Dis"},{"key":"e_1_2_1_28_2","first-page":"543","article-title":"Clinical evaluation of cefoperazone in the treatment of urinary tract infection in urological practice","volume":"31","author":"Wespes E","year":"1982","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02013918"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/10.3.207"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/148.5.892"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198427060-00001"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01644235"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238442"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/19.6.823"},{"key":"e_1_2_1_36_2","first-page":"873","article-title":"Ceftriaxone effect on bilirubin\u2010albumin binding","volume":"80","author":"Fink S","year":"1987","journal-title":"Pediatrics"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80072-6"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01644225"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.suppl_A.81"},{"key":"e_1_2_1_40_2","first-page":"373","article-title":"Cefsulodin and ceftazidime, two antipseudomonal cephalosporins","volume":"3","author":"Smith BR","year":"1984","journal-title":"Clin Pharm"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90267-0"},{"key":"e_1_2_1_42_2","first-page":"1629","volume-title":"The Metabolic Bass of Inherited Disease","author":"Beutler E","year":"1983"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/160.3.442"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-4-469"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-4-495"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80621-7"},{"key":"e_1_2_1_47_2","unstructured":"Package insert Claforan\u00ae December 1989."},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160110017004"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/11.suppl_C.43"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-6-924"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198711000-00007"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92487-X"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.6.1108"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90256-1"},{"key":"e_1_2_1_55_2","first-page":"52","article-title":"Cefoperazone\u2014sulbactam combination in the treatment of urinary tract infections: Efficacy, safety, and effects on coagulation","volume":"10","author":"Greenberg RN","year":"1987","journal-title":"Clin Ther"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90228-6"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)31442-0"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90324-7"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/16.2.235"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/22.5.687"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1990.tb03476.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1990.tb03476.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T18:13:48Z","timestamp":1697998428000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1990.tb03476.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1990,5]]}},"alternative-id":["10.1002\/j.1552-4604.1990.tb03476.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1990.tb03476.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,5]]}}}